Tudor Investment Corp ET AL Acquires Shares of 25,465 Twist Bioscience Corporation $TWST

Key Points

• Tudor Investment bought a new position of 25,465 shares in Twist Bioscience (≈$717,000), and other institutions also raised stakes — notably Goldman Sachs now holds 932,978 shares after adding 37,577.
• Insiders sold stock in the last quarter (including CFO Adam Laponis selling 7,000 shares at $50 and Dennis Cho selling 5,000 at $49.93), totaling 48,190 shares worth about $2.23 million; insiders now own 3.08% of the company.
• Twist shares were trading up ~9.8% (opened $47.52) with a 52‑week range of $23.30–$57.88; revenue rose 16.9% YoY but the company remains unprofitable, and analysts have a consensus rating of Moderate Buy with a $46.50 target.

Tudor Investment Corp ET AL bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 25,465 shares of the company's stock, valued at approximately $717,000.

Other large investors have also recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock valued at $1,585,000 after buying an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Twist Bioscience by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company's stock valued at $2,765,000 after buying an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock valued at $36,629,000 after acquiring an additional 37,577 shares during the period. Intech Investment Management LLC raised its holdings in Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock valued at $1,135,000 after acquiring an additional 4,591 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Twist Bioscience by 22.0% during the second quarter. Legal & General Group Plc now owns 110,286 shares of the company's stock worth $4,057,000 after acquiring an additional 19,915 shares in the last quarter.

Insider Activity

In related news, CFO Adam Laponis sold 7,000 shares of the firm's stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the sale, the chief financial officer directly owned 130,031 shares of the company's stock, valued at $6,501,550. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Dennis Cho sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00. Following the sale, the insider owned 138,581 shares of the company's stock, valued at approximately $6,919,349.33. The trade was a 3.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 48,190 shares of company stock worth $2,234,695. Company insiders own 3.08% of the company's stock.

Twist Bioscience Trading Up 9.8%

Shares of TWST stock opened at $47.52 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $57.88. The company has a market capitalization of $2.91 billion, a PE ratio of -37.13 and a beta of 2.23. The business's fifty day moving average is $46.62 and its 200 day moving average is $36.94.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analysts' expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business's revenue for the quarter was up 16.9% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

TWST has been the subject of several recent research reports. Guggenheim lifted their price target on Twist Bioscience from $50.00 to $55.00 and gave the company a "buy" rating in a research report on Monday. Robert W. Baird set a $50.00 target price on Twist Bioscience in a research note on Tuesday, February 3rd. Evercore lifted their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a report on Tuesday, February 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Friday. Finally, TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a report on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $46.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.